Pharmacy & Biological Sciences
Category
Insulin’s Steep Price Leads To Deadly Rationing
The price of insulin in the U.S. has more than doubled since 2012. Because of this, some diabetics have been forced to take drastic measures, like rationing their insulin.
New Guidances Issued to Promote Generic Drug Access and Drug Price Competition
The guidances issued today by the FDA are part of a larger initiative by the administration to increase patient access to high-quality generics.
China Withholding Deadly Flu Samples from U.S. Researchers
Americans have zero immunity against the deadly H7N9 flu, and China is refusing to share much-needed samples with U.S. Researchers hoping to combat a potential outbreak.
First Generic EpiPen Approved by FDA
On the heels of a massive EpiPen shortage, the U.S. Food and Drug Administration has approved the first generic alternative.
Trump Administration Sinks Teeth Into Paring Down Drug Prices, On 5 Key Points
Three months after President Trump announced his blueprint to bring down drug prices, administration officials have begun putting some teeth behind the rhetoric.
“Ask Your Doctor About…” Coming to a Computer Near You?
Digital ads for prescriptions are approaching parity with TV ads, with an even larger percentage of patients who saw ads online asking their doctors about specific medications.
R&D Spend Hit Record High for Biopharma Companies in 2017
Biopharma companies invested a total of $71.4 billion in research and development in 2017, up from $65.5 billion in 2016 and a record high.
US Congressman/Former BioPharma Company Board Member Arrested
Chris Collins, the United States Representative for New York’s 27th congressional district, has been arrested by the FBI on charges of insider trading.
FDA Supports New Steps to Further Nicotine Replacement Therapy Research
Use of FDA-approved nicotine replacement therapy products may double the likelihood of a successful attempt to quit smoking.
Biopharma Seeks Balance
Biopharma companies can balance competing demands from patients, investors, and regulators by keeping their focus on the science.